These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

92 related articles for article (PubMed ID: 17918790)

  • 1. Immunohistochemical prognostic markers in bladder cancer.
    Ioachim E; Stavropoulos NE; Charalabopoulos K; Agnantis NJ
    J BUON; 2002; 7(3):207-16. PubMed ID: 17918790
    [TBL] [Abstract][Full Text] [Related]  

  • 2. ETS transcription factors and their emerging roles in human cancer.
    Seth A; Watson DK
    Eur J Cancer; 2005 Nov; 41(16):2462-78. PubMed ID: 16213704
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Molecular alterations associated with bladder cancer initiation and progression.
    Cordon-Cardo C
    Scand J Urol Nephrol Suppl; 2008 Sep; (218):154-65. PubMed ID: 18815930
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Molecular mechanism of cancer seeding: adhesion molecules and signal transduction networks].
    Mareel M; Vermeulen S; Bracke M
    Verh K Acad Geneeskd Belg; 1997; 59(4):327-51. PubMed ID: 9490922
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Decreased expression of galectin-3 predicts tumour recurrence in pTa bladder cancer.
    Kramer MW; Kuczyk MA; Hennenlotter J; Serth J; Schilling D; Stenzl A; Merseburger AS
    Oncol Rep; 2008 Dec; 20(6):1403-8. PubMed ID: 19020721
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Loss expression of uroplakin III is associated with clinicopathologic features of aggressive bladder cancer.
    Matsumoto K; Satoh T; Irie A; Ishii J; Kuwao S; Iwamura M; Baba S
    Urology; 2008 Aug; 72(2):444-9. PubMed ID: 18313120
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Cancer genetics. A review of oncological molecular biology seen in relation to the human genome].
    Gerdes AM
    Ugeskr Laeger; 2002 May; 164(22):2865-71. PubMed ID: 12082811
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Overexpression of CDC91L1 (PIG-U) in bladder urothelial cell carcinoma: correlation with clinical variables and prognostic significance.
    Shen YJ; Ye DW; Yao XD; Trink B; Zhou XY; Zhang SL; Dai B; Zhang HL; Zhu Y; Guo Z; Wu G; Nagpal J
    BJU Int; 2008 Jan; 101(1):113-9. PubMed ID: 17941920
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The hamster model of sequential oral oncogenesis.
    Vairaktaris E; Spyridonidou S; Papakosta V; Vylliotis A; Lazaris A; Perrea D; Yapijakis C; Patsouris E
    Oral Oncol; 2008 Apr; 44(4):315-24. PubMed ID: 18061531
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [The complexity of interactions of the tumour growth process].
    Valásková Z; Kinová S; Danihel L; Duris I; Markovicová D; Mravec B; Hulín I
    Vnitr Lek; 2009 Dec; 55(12):1145-58. PubMed ID: 20070031
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Energy balance, physical activity, and cancer risk.
    Fair AM; Montgomery K
    Methods Mol Biol; 2009; 472():57-88. PubMed ID: 19107429
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Differentiation: an encouraging approach to anticancer therapy.
    Marchal JA; Rodríguez-Serrano F; Campos J; Madeddu R; Boulaiz H; Martínez-Amat A; Carrillo E; Caba O; Prados JC; Vélez C; Melguizo C; Montella A; Aránega A
    Ital J Anat Embryol; 2006; 111(1):45-64. PubMed ID: 16736717
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prognostic markers for bladder cancer: International Consensus Panel on bladder tumor markers.
    Habuchi T; Marberger M; Droller MJ; Hemstreet GP; Grossman HB; Schalken JA; Schmitz-Dräger BJ; Murphy WM; Bono AV; Goebell P; Getzenberg RH; Hautmann SH; Messing E; Fradet Y; Lokeshwar VB
    Urology; 2005 Dec; 66(6 Suppl 1):64-74. PubMed ID: 16399416
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Oral squamous cell carcinoma and biological markers: an update on the molecules mainly involved in oral carcinogenesis.
    Lo Muzio L; Santarelli A; Panzarella V; Campisi G; Carella M; Ciavarella D; Di Cosola M; Giannone N; Bascones A
    Minerva Stomatol; 2007 Jun; 56(6):341-7. PubMed ID: 17625491
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Are critical normal gene products in cancer cells the real therapeutic targets?
    Warenius HM
    Anticancer Res; 2002; 22(5):2651-5. PubMed ID: 12529977
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Growth hormone in vascular pathology: neovascularization and expression of receptors is associated with cellular proliferation.
    Lincoln DT; Singal PK; Al-Banaw A
    Anticancer Res; 2007; 27(6B):4201-18. PubMed ID: 18225592
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cancer invasion and metastasis: changing views.
    Duffy MJ; McGowan PM; Gallagher WM
    J Pathol; 2008 Feb; 214(3):283-93. PubMed ID: 18095256
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Prevention of cancer and the dose-effect relationship: the carcinogenic effects of ionizing radiations].
    Tubiana M
    Cancer Radiother; 2009 Jul; 13(4):238-58. PubMed ID: 19539515
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Generalities about carcinogenesis].
    Tubiana M
    C R Biol; 2008 Feb; 331(2):114-25. PubMed ID: 18241804
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Metastasis markers in bladder cancer: a review of the literature and clinical considerations.
    Gontero P; Banisadr S; Frea B; Brausi M
    Eur Urol; 2004 Sep; 46(3):296-311. PubMed ID: 15306099
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.